Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Protein Interaction Maps*; Biomarkers, Tumor/*genetics ; Carcinoma, Non-Small-Cell Lung/*genetics ; Lung Neoplasms/*genetics; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms/metabolism ; Transcriptome

Small cell lung cancer (SCLC) is a carcinoma of the lungs with strong invasion, poor prognosis and resistant to multiple chemotherapeutic drugs. It has posed severe challenges for the effective treatment of lung cancer. Therefore, searching for genes related to the development and prognosis of SCLC and uncovering their underlying molecular mechanisms are urgent problems to be resolved. This study is aimed at exploring the potential pathogenic and prognostic crucial genes and key pathways of SCLC via bioinformatic analysis of public datasets. Firstly, 117 SCLC samples and 51 normal lung samples were collected and analyzed from three gene expression datasets. Then, 102 up-regulated and 106 down-regulated differentially expressed genes (DEGs) were observed. And then, functional annotation and pathway enrichment analyzes of DEGs was performed utilizing the FunRich. The protein-protein interaction (PPI) network of the DEGs was constructed through the STRING website, visualized by Cytoscape. Finally, the expression levels of eight hub genes were confirmed in Oncomine database and human samples from SCLC patients. It showed that CDC20, BUB1, TOP2A, RRM2, CCNA2, UBE2C, MAD2L1, and BUB1B were upregulated in SCLC tissues compared to paired adjacent non-cancerous tissues. These suggested that eight hub genes might be viewed as new biomarkers for prognosis of SCLC or to guide individualized medication for the therapy of SCLC.
Competing Interests: The authors have declared that no competing interests exist.

Cancer Lett. 2009 Apr 18;276(2):228-38. (PMID: 19111388)
Genomics. 1998 May 1;49(3):475-8. (PMID: 9615237)
Cancers (Basel). 2018 Jul 27;10(8):. (PMID: 30060526)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Cell Rep. 2020 Mar 17;30(11):3837-3850.e3. (PMID: 32187553)
Front Oncol. 2020 Apr 07;10:498. (PMID: 32318351)
J Thorac Oncol. 2015 Aug;10(8):1213-20. (PMID: 26200277)
Mol Cell. 2018 May 3;70(3):395-407.e4. (PMID: 29727616)
Endocr Relat Cancer. 2013 May 21;20(3):361-70. (PMID: 23533247)
Lancet Oncol. 2016 Jul;17(7):883-895. (PMID: 27269741)
J Extracell Vesicles. 2017 May 26;6(1):1321455. (PMID: 28717418)
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5. (PMID: 11707567)
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4459-64. (PMID: 15070740)
FASEB J. 2019 Jan;33(1):1374-1388. (PMID: 30138038)
Int J Oncol. 1997 May;10(5):885-93. (PMID: 21533458)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Brief Bioinform. 2019 Jul 19;20(4):1420-1433. (PMID: 29415187)
Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. (PMID: 30996073)
Cancer Res. 2017 Oct 15;77(20):5518-5529. (PMID: 28855212)
Oncogenesis. 2018 Jun 13;7(6):49. (PMID: 29904125)
Lung Cancer. 2018 Jan;115:42-48. (PMID: 29290260)
J Clin Oncol. 2012 Mar 10;30(8):863-70. (PMID: 22215748)
Nat Cell Biol. 2013 Jan;15(1):96-102. (PMID: 23242215)
Int J Cancer. 2007 Jul 1;121(1):33-8. (PMID: 17354233)
J Surg Oncol. 2012 Sep 15;106(4):423-30. (PMID: 22488197)
Med Oncol. 2015 May;32(5):149. (PMID: 25832867)
J Clin Oncol. 2012 Mar 10;30(8):878-9. (PMID: 22215755)
Front Oncol. 2019 Oct 22;9:1103. (PMID: 31696057)
Neoplasia. 2007 Feb;9(2):166-80. (PMID: 17356713)
Cancer Lett. 2007 Sep 8;254(2):298-307. (PMID: 17498870)
Med Sci Monit. 2018 Oct 22;24:7541-7547. (PMID: 30346937)
J Cancer Res Clin Oncol. 2010 Mar;136(3):419-26. (PMID: 19779934)
Tumour Biol. 2016 Jan;37(1):749-62. (PMID: 26245990)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Nat Commun. 2016 Nov 15;7:13398. (PMID: 27845331)
J Cancer. 2019 May 21;10(10):2176-2184. (PMID: 31258721)
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17034-9. (PMID: 23035247)
Mol Med Rep. 2018 Aug;18(2):1538-1550. (PMID: 29845250)
Nat Commun. 2018 Sep 17;9(1):3787. (PMID: 30224629)
Neoplasia. 2014 May;16(5):390-402. (PMID: 25016594)
J Cell Physiol. 2018 Oct;233(10):6759-6767. (PMID: 29667764)
Trends Biochem Sci. 2011 Mar;36(3):141-50. (PMID: 20888775)
Mol Med Rep. 2019 Sep;20(3):2199-2208. (PMID: 31257520)
Oncol Rep. 2006 Oct;16(4):859-64. (PMID: 16969506)
Front Genet. 2018 Oct 12;9:469. (PMID: 30369945)
Oncotarget. 2016 Nov 15;7(46):75165-75175. (PMID: 27738335)
Onco Targets Ther. 2019 Nov 20;12:9927-9939. (PMID: 31819489)
Exp Ther Med. 2018 Apr;15(4):3273-3282. (PMID: 29545845)
Cancer Lett. 2001 Jan 26;162(2):201-5. (PMID: 11146226)
Nucleic Acids Res. 2019 Jan 8;47(D1):D948-D954. (PMID: 30247620)
Oncogene. 2008 Mar 6;27(11):1562-71. (PMID: 17873905)
Lung Cancer. 2011 Oct;74(1):124-31. (PMID: 21376419)
Oncol Lett. 2019 Oct;18(4):3723-3733. (PMID: 31516585)
Front Immunol. 2017 Sep 04;8:1063. (PMID: 28928739)
Genome Res. 2009 Sep;19(9):1639-45. (PMID: 19541911)
Nat Genet. 2012 Oct;44(10):1104-10. (PMID: 22941188)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Biochem Pharmacol. 2000 Oct 15;60(8):1179-84. (PMID: 11007956)
Br J Cancer. 2009 Jul 7;101(1):166-73. (PMID: 19513072)
Genes (Basel). 2019 Oct 30;10(11):. (PMID: 31671531)
PLoS One. 2014 Mar 12;9(3):e91771. (PMID: 24622579)
Pathology. 2019 Aug;51(5):481-486. (PMID: 31230818)
Gastroenterology. 2007 Jun;132(7):2448-58. (PMID: 17570218)
Nat Genet. 2016 May;48(5):563-8. (PMID: 27064253)
J Comput Biol. 2017 Jul;24(7):647-662. (PMID: 28541721)
J Clin Oncol. 2014 Dec 10;32(35):4012-9. (PMID: 25385727)
Cancer Res. 1994 Feb 1;54(3):756-62. (PMID: 8306338)
Cancer Discov. 2013 Feb;3(2):198-211. (PMID: 23154965)
Pharmacol Ther. 2017 Dec;180:16-23. (PMID: 28579387)
Nature. 2007 Aug 2;448(7153):561-6. (PMID: 17625570)
Nat Commun. 2017 Jun 12;8:15822. (PMID: 28604727)
J Clin Oncol. 2016 Nov 1;34(31):3740-3748. (PMID: 27458307)
BMC Bioinformatics. 2003 Jan 13;4:2. (PMID: 12525261)
N Engl J Med. 2004 May 20;350(21):2129-39. (PMID: 15118073)
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368. (PMID: 27924014)
Cancer Res. 2000 Aug 15;60(16):4349-52. (PMID: 10969775)
J Cancer. 2019 Jul 10;10(18):4208-4216. (PMID: 31413739)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
J Cancer. 2019 Oct 21;10(26):6618-6634. (PMID: 31777591)
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9. (PMID: 11707590)
J Natl Cancer Inst. 2009 May 6;101(9):644-50. (PMID: 19401546)
Science. 2004 Oct 22;306(5696):636-40. (PMID: 15499007)
Cell Rep. 2018 Feb 6;22(6):1424-1438. (PMID: 29425499)
Trends Mol Med. 2015 Jun;21(6):364-72. (PMID: 25964054)
Cell Cycle. 2014;13(22):3590-601. (PMID: 25483095)
PLoS One. 2017 Mar 16;12(3):e0172316. (PMID: 28301542)
Eur J Med Chem. 2017 Feb 15;127:235-249. (PMID: 28064078)

0 (Biomarkers, Tumor)

Date Created: 20201113 Date Completed: 20210101 Latest Revision: 20210101

20240105

PMC7665632

10.1371/journal.pone.0242194

33186389